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Abstract
Background: It is unclear whether high-density lipoprotein cholesterol (HDL-C) level predicts cardio-
vascular events and has a protective effect in patients with acute myocardial infarction (AMI) undergo-
ing percutaneous coronary intervention (PCI) and statin treatment.
Methods: A total of 15,290 AMI patients receiving statins were selected from the Korean Myocardial 
Infarction Registry. Baseline HDL-C level was used to identify patients with low (group A), normal 
(group B), and high (group C) HDL-C levels according to the Adult Treatment Panel III criteria. Clini-
cal outcomes were compared in propensity-adjusted and matched cohorts. The primary endpoint was  
a composite of cardiovascular death and recurrent myocardial infarction. 
Results: At the median follow-up of 11.5 months, the primary endpoint occurred in 2.7% (112/4098), 
1.4% (54/3910), and 1.2% (8/661) of patients in groups A, B, and C, respectively. In the propensity-
-adjusted cohort, low HDL-C level increased the risk of primary endpoint (hazard ratio [HR] 1.755, 
95% confidence interval [CI] 1.274–2.417, p = 0.001), whereas high HDL-C level did not reduce this 
risk (HR 0.562, 95% CI 0.275–1.146, p = 0.113). In the propensity-matched cohort, low HDL-C level 
increased the risk of primary endpoint (HR 1.716, 95% CI 1.210–2.434, p = 0.002), whereas high 
HDL-C level reduced this risk (HR 0.449, 95% CI 0.214–0.946, p = 0.035).
Conclusions: In AMI patients treated with PCI and statins, low HDL-C level increases the risk of 
cardiovascular death and recurrent myocardial infarction, whereas high HDL-C level likely reduces 
the risk of cardiovascular events, especially for ST-elevation myocardial infarction. (Cardiol J 2019; 
26, 2: 176–185)
Key words: high-density lipoprotein cholesterol, acute myocardial infarction,  
cardiovascular events, statin
Introduction
Several randomized control trials have shown 
that persistent cardiovascular risk remains in spite 
of reducing the level of low-density lipoprotein cho-
lesterol (LDL-C) with intensive statin therapy [1]. 
In contrast, an inverse relation between the level 
of high-density lipoprotein cholesterol (HDL-C) 
and the rate of cardiovascular events has been 
revealed in a number of studies [2, 3]. A high 
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HDL-C level is associated with cardioprotective 
and anti-inflammatory effects, and achieving it rep-
resents a potential therapeutic strategy to reduce 
cardiovascular risk [4].
Whether low HDL-C levels predict poor car-
diovascular outcomes in acute myocardial infarction 
(AMI) patients has been a matter of controversy 
[5, 6]. In this regard, vascular effects of HDL-C can 
be highly heterogeneous in various clinical conditions 
[7], and its anti-inflammatory function may be im-
paired in patients with coronary artery disease (CAD) 
[8]. It is therefore important to verify the protective 
role of high HDL-C levels in patients with AMI.
In the present study, the predictive and pro-
tective role of HDL-C in a cohort of Asian patients 
with AMI undergoing percutaneous coronary 
intervention (PCI) and intensive statin therapy 
were evaluated.
Methods
Study population
In this prospective, multicenter, observational 
registry-based study, the data of 31,149 patients 
with ST-elevation myocardial infarction (STEMI) 
and non-STEMI (NSTEMI) from 53 hospitals 
were retrieved from the Korean Acute Myocardial 
Infarction Registry (KAMIR) between 2006 and 
2012 [9, 10]. This was retrospective study based 
on the KAMIR registry. The 53 participating cent-
ers included high-volume university or community 
hospitals with facilities for PCI and on-site cardiac 
surgery. The study protocol conformed to the ethi-
cal guidelines of the 1975 Declaration of Helsinki as 
reflected by prior approval by the human research 
committee of each participating institution. In-
formed consent for use of data was obtained from 
each patient. Clinical and laboratory characteristics 
and outcomes were collected by trained study co-
ordinators using a standardized case report form 
and protocol. Angiographic characteristics such as 
American College of Cardiology/American Heart 
Association (ACC/AHA) lesion type or throm-
bolysis in myocardial infarction (TIMI) flow grade 
were assessed by the surgeons. Clinical follow-up 
was performed at 1, 2, 6, 12, and 24 months after 
discharge from hospital.
The inclusion criteria for the present study 
were as follows: (1) age ≥ 18 years; (2) diagnosis 
of STEMI or NSTEMI; (3) absence of clinical 
events during hospitalization; and (4) statins use 
at discharge. The exclusion criterion was missing 
information on serum HDL-C level.
Among the 31,149 patients registered in the 
above mentioned database, a total of 15,290 AMI 
patients treated with statins were eligible for this 
study. The patients were divided into three groups 
based on serum HDL-C levels at baseline accord-
ing to the Adult Treatment Panel III (ATP III) 
guidelines (group A: 7,308 patients with low 
HDL-C, group B: 6,827 patients with normal 
HDL-C, group C: 1,155 patients with high HDL-C) 
(Fig. 1). The median follow-up period was 347 
days (interquartile range: 59–403 days). Follow-up 
information was obtained in 14,830 patients (97%, 
excluding 460 patients who died during hospitaliza-
tion) among the initial 15,290 patients.
Definitions and outcomes
Blood samples were collected at admission, 
except for the samples used for obtaining lipid pro-
files, which were collected after overnight fasting.
According to the ATP III guidelines [11], a low 
HDL-C level (group A) was defined as a concentra-
tion of HDL-C below 40 mg/dL for men and 50 mg/dL 
for women. A high HDL-C level (group C) was de-
fined as a concentration of HDL-C over 60 mg/dL. 
A normal HDL-C level (group B) was defined as 
an HDL-C concentration between the limits of the 
low and high HDL-C groups.
The primary outcome was the composite of 
cardiovascular death and recurrent MI during the 
follow-up period. Secondary outcomes included 
cardiovascular death, all-cause death, recurrent MI, 
any revascularization, and major adverse cardiac 
events (MACE), which included all-cause death, 
recurrent MI, and any revascularization during 
the follow-up. All events were identified by the 
patient’s physician and confirmed by the principal 
investigator of each hospital.
Statistical analyses
Continuous variables were compared using 
Student’s t-test or the Wilcoxon rank-sum test, 
and categorical variables were compared using 
the c2 test or Fisher’s exact test, as appropri-
ate. Because of significant differences in a large 
number of baseline clinical and angiographic 
characteristics between the three groups, propen-
sity score adjustment was performed. Since only 
pairwise comparisons are allowed in propensity 
score adjustment, the groups were combined and 
compared in the following manner: low HDL-C 
group vs. combined normal-high HDL-C group 
and combined low-normal HDL-C group vs. high 
HDL-C group.
178 www.cardiologyjournal.org
Cardiology Journal 2019, Vol. 26, No. 2
In the main analysis, a propensity score was 
calculated and used to adjust the between-group 
comparisons of cardiovascular outcomes [12]. 
The propensity score was estimated using a non-
parsimonious multivariate logistic regression 
model, with low HDL-C level or high HDL-C level 
in each subgroup as the dependent variable and 
characteristics that potentially affect cardiovascular 
outcomes, including age, sex, history of ischemic 
heart disease, hypertension, diabetes, dyslipidem-
ia, smoking status, Killip class, number of diseased 
vessels, post-TIMI flow, initial left ventricular ejec-
tion fraction (LVEF), serum creatinine level, serum 
glucose level, peak troponin I, and use of acetylsali-
cylic acid, clopidogrel, beta-blockers, angiotensin 
converting enzyme inhibitors, aldosterone receptor 
blockers, spironolactone, and insulin.
An additional analysis was performed on matched 
pairs of patients between each subgroup (group A vs. 
group B + C, group A + B vs. group C). Each propen-
sity score matching was performed using the nearest 
neighbor method (1:1 for group A vs. group B + C, 
3:1 for group A + B vs. group C without replacement) 
with a caliper width of 0.1. Absolute standardized dif-
ferences for all covariates before and after matching 
were estimated to evaluate bias reduction using the 
propensity score matching method. After propensity 
score matching, all absolute standardized differences 
were below 10%, indicating adequate matching. 
Comparisons of baseline clinical and angiographic 
characteristics between the matched groups were 
performed using Student’s t-test for continuous vari-
ables and the c2 test for categorical variables.
Risk of negative cardiovascular outcomes 
between all the subgroups in the propensity score-
adjusted cohort were compared using the Cox 
proportional hazard regression model with the 
propensity score as a covariate. Adjusted cumu-
lative survival curves were calculated using the 
corrected group prognosis method. A secondary 
analysis was done using the Cox proportional 
hazard regression model stratified on the matched 
pairs. Proportional hazard assumptions were tested 
by using the log–log survival plot and Schoenfeld 
residuals. Subgroup analysis was also performed 
only in the propensity score-matched cohort based 
on the type of MI (STEMI or NSTEMI).
Sensitivity analysis was performed to assess 
the robustness of results. An inverse probability 
of treatment weight (IPTW) approach was used 
because it utilizes the whole patient population 
rather than the reduced population obtained by 
the propensity score matching, resulting in greater 
power and precision [13].
Figure 1. Study flowchart; AMI — acute myocardial infarction; HDL-C — high-density lipoprotein cholesterol; KAMIR 
— the Korean Acute Myocardial Infarction Registry.
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A multiple Cox regression analysis was per-
formed to predict risk factors of negative cardiovas-
cular outcome during the follow-up using baseline 
and angiographic characteristics associated with 
cardiac death and MI in a simple Cox regression 
analysis (p < 0.1) with > 90% data availability.
All reported p values were 2-sided, and 
p values < 0.05 were considered to indicate sta-
tistically significant differences. All analyses were 
performed with SPSS 21.0 for Windows (SPSS Inc., 
Chicago, IL) and R (version 2.14.2) using freely 
distributed statistical packages, as well as SAS soft-
ware, version 9.3 (SAS Institute, Cary, NC, USA).
Results
Major differences in baseline and angiographic 
characteristics between the three groups were con-
sistently found in propensity score-adjusted cohort 
(Table 1). After matching between divided sub-
groups, all absolute standardized differences were 
within 10%, which suggests adequate matching.
Overall study outcomes 
In the propensity score-adjusted cohort, 174 
(2%) patients experienced at least one primary 
event (cardiovascular death or recurrent MI) dur-
ing the follow-up period. The rate of primary out-
come was highest in low HDL-C group (group A) 
and similar in normal and high HDL-C groups (groups 
B and C) (Fig. 2). An increased risk of primary out-
come (hazard ratio [HR] 1.755, confidence interval 
[CI] 1.274–2.417, p = 0.001) was found in group A, 
which was driven by an increase in cardiovascu-
lar death (HR 2.233, CI 1.465–3.404, p < 0.001) 
and eventually in all-cause death (HR 1.486, CI 
1.084–2.036, p = 0.014), whereas the risk of primary 
outcome was not reduced in group C (HR 0.562, CI 
0.275–1.146, p = 0.113) (Table 2). There were no 
differences in the risk of MI recurrence and MACE.
Outcomes in patients with  
low HDL-C level
When these analyses were repeated in the 
matched cohort (group A vs. group B + C), risk of 
primary outcome was increased in Group A (2.5% 
vs. 1.5%, HR 1.716, CI 1.210–2.434, p = 0.002) 
(Fig. 3A, Table 3). There were no differences in 
the risks of MI recurrence, all-cause death, and 
MACE between the groups. 
Analyses by the propensity score matching 
method were repeated in the subgroups including 
STEMI and NSTEMI patients. In the matched 
cohort (group A vs. group B + C), low HDL-C 
level tended to be associated with an increased 
risk of primary outcome in STEMI patients, but 
the difference was not statistically significant (HR 
1.542, CI 0.969–2.453, p = 0.068). In contrast, low 
HDL-C level was associated with an increased risk 
of primary outcome in NSTEMI patients (HR 2.058, 
CI 1.195–3.546, p = 0.009).
Outcomes in patients with  
high HDL-C level
The analysis of the second matched cohort 
(group A + B vs. group C) revealed a decrease in 
risk of primary outcome (2.7% vs. 1.2%, HR 0.449, 
CI 0.214–0.946, p = 0.035) (Fig. 3B, Table 3). 
There were no differences in the risk of secondary 
outcomes. The analyses by the propensity score 
matching method were repeated in STEMI and 
NSTEMI subgroups. Interestingly, high HDL-C 
level was associated with a reduction in the risk of 
primary outcome in the STEMI patients (HR 0.267, 
CI 0.081–0.873, p = 0.029) but not in the NSTEMI 
patients (HR 0.774, CI 0.292–2.053, p = 0.606).
Sensitivity analysis
Sensitivity analyses were performed for the 
primary outcome using weighted Cox regres-
sion by the IPTW method. An increased risk of 
cardiovascular death and MI was found in the low 
HDL-C group (HR 1.758, 95% CI 1.414–2.186, 
p < 0.001). Furthermore, the risk of cardiovascular 
death and MI was reduced in the high HDL-C group 
(HR 0.632, 95% CI 0.500–0.797, p < 0.001). This 
confirmed the results of the main analyses.
Independent predictors  
of cardiovascular events
The simple Cox regression analysis of the 
propensity score-adjusted cohort showed that old 
age, female sex, high Killip class, history of prior 
ischemic heart disease, hypertension, diabetes 
mellitus, three-vessel disease, post-procedural 
TIMI flow grades 2 and 3, low LVEF, high serum 
levels of glucose or creatinine at presentation, and 
high peak serum level of troponin were associ-
ated with cardiovascular death and MI during the 
follow-up (Table 4). After the adjustment for old 
age, high Killip class, and low LVEF continued to 
show a significant association with cardiovascular 
death and MI during the follow-up.
Discussion
In the present study, the predictive and pro-
tective role of HDL-C in AMI patients was inves-
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Table 1. Baseline clinical and procedural characteristics.
Group A Group B Group C P
Low HDL-C  
(n = 4,098)
Normal HDL-C  
(n = 3,910)
High HDL-C  
(n = 661)
Age [years] 62.2 ± 12.6 63.1 ± 12.6 64.3 ± 12.2 < 0.001
Male sex 5972 (78%) 7606 (70%) 590 (62.6%) < 0.001
Ischemic heart disease 1181 (15.5%) 1525 (14.1%) 232 (14.8%) 0.028
Diabetes mellitus 2418 (32.1%) 2651 (24.7%) 317 (20.2%) < 0.001
Hypertension 3804 (50.3%) 5321 (49.5%) 753 (48.1%) 0.251
Dyslipidemia 956 (13.6%) 1297 (13.0%) 157 (10.8%) 0.014
Smoking 3735 (49.4%) 4597 (42.7%) 578 (37.1%) < 0.001
Family history of ischemic heart disease 659 (9.3%) 889 (8.9%) 113 (7.8%) 0.178
Systolic BP at presentation [mmHg] 127 ± 30 130 ± 27 133 ± 27 < 0.001
Diastolic BP at presentation [mmHg] 78 ± 27 79 ± 17 81 ± 16 < 0.001
Killip class:
I 5412 (75.1%) 7844(76.3%) 1056 (70.7%) < 0.001
II 910 (12.6%) 1346 (13.1%) 242 (16.2%)
III 565 (7.8%) 752 (7.3%) 142 (9.5%)
IV 320 (4.4%) 336 (3.3%) 53 (3.5%)
Door-to-balloon time [min] 173 ± 196 176 ± 199 179 ± 208 0.576
Left ventricular ejection fraction [%] 52.4 ± 11.6 52.5 ± 13.1 52.2 ± 15.6 0.538
Peak troponin I [ng/mL] 39.9 ± 88.2 44.2 ± 116.5 49.6 ± 255.5 0.015
Serum creatinine [mg/dL] 1.25 ± 1.54 1.10 ± 1.4 1.05 ± 1.07 < 0.001
Serum glucose [mg/dL] 171.6 ± 82.4 165.3 ± 74.5 164.9 ± 74.4 < 0.001
Total cholesterol [mg/dL] 172 ± 44 189 ± 42 201 ± 45 < 0.001
HDL-C [mg/dL] 33 ± 5 47 ± 5 70 ± 13 < 0.001
LDL-C [mg/dL] 110 ± 37 120 ± 41 117 ± 42 < 0.001
Triglycerides [mg/dL] 150 ± 116 120 ± 93 102 ± 88 < 0.001
C-reactive protein [mg/dL] 11.00 ± 56.48 9.13 ± 52.90 8.30 ± 53.99 0.059
Medications at discharge:
Acetylsalicylic acid 7520 (98.2%) 10661 (98.1%) 1543 (97.7%) 0.312
Clopidogrel 7269 (94.9%) 10241 (94.3%) 1455 (92.3%) < 0.001
Calcium channel blockers 734 (9.8%) 1075 (10.1%) 171 (11.1%) 0.3
Beta-adrenergic blockers 6061 (79.5%) 8534 (78.8%) 1217 (77.4%) 0.148
ACE inhibitors 4710 (62%) 6972 (64.8%) 1032 (65.9%) < 0.001
Angiotensin receptor blockers 1652 (22%) 2228 (20.8%) 291 (18.8%) 0.011
Spironolactone 621 (8.3%) 901 (8.5%) 120 (7.8%) 0.645
Insulin 127 (1.7%) 152 (1.4%) 12 (0.8%) 0.02
Oral hypoglycemic agents 1201 (15.7%) 1499 (13.8%) 214 (13.5%) 0.001
Number of diseased vessels: < 0.001
1 2861 (40.4%) 4588 (46%) 701 (51.4%)
2 2180 (30.8%) 2966 (29.7%) 402 (29.5%)
3 1808 (25.5%) 2140 (21.4%) 232 (17%)
Left main disease 229 (3.2%) 288 (2.9%) 30 (2.2%)
Culprit lesion: < 0.001
Left anterior descending 3022 (42.9%) 4952 (49.8%) 747 (54.9%)
Left circumflex 1238 (17.6%) 1712 (17.2%) 228 (16.8%)
Right coronary artery 2646 (37.6%) 3111 (31.3%) 360 (26.5%)
Left main tract 134 (1.9%) 170 (1.7%) 26 (1.9%)
Successful PCI 6466 (97.6%) 9161 (97.5%) 1226 (96.8%) 0.403
Post-procedural TIMI flow grade: 0.125
0 112 (1.7%) 116 (1.3%) 23 (1.8%)
1 61 (0.9%) 79 (0.9%) 13 (1%)
2 229 (3.6%) 354 (3.9%) 56 (4.5%)
3 6023 (93.7%) 8542 (94%) 1155 (92.6%)
ACE — angiotensin converting enzyme; BP — blood pressure; HDL-C — high-density lipoprotein cholesterol; LDL-C — low-density lipoprotein 
cholesterol; PCI — percutaneous coronary intervention; TIMI — thrombolysis in myocardial infarction
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tigated. evidence was found that the initial level 
of HDL-C affected cardiovascular outcomes in 
a cohort of Asian patients with acute AMI that 
were treated with statins. Thus, the rate of car-
diovascular death and MI recurrence was higher 
in the patients with low HDL-C level, whereas 
high HDL-C level was associated with a lower 
rate of major cardiovascular events. Importantly, 
the application of different adjustment methods 
did not affect these findings. Moreover, subgroup 
analyses revealed that low HDL-C level was as-
sociated with a significantly higher risk of major 
cardiovascular events in the NSTEMI patients 
and only a modestly increased risk in the STEMI 
patients. Finally, high HDL-C level was associated 
with a lower risk of major cardiovascular events 
only in STEMI patients.
Lower HDL-C levels have been shown to be 
associated with a higher risk of cardiovascular 
events and greater severity of atherosclerosis 
even in patients with lower LDL levels, including 
those treated with statins [2]. Moreover, several 
studies have demonstrated that low HDL-C level in 
NSTEMI patients was predictive of major adverse 
cardiovascular events [5, 14]. In addition, low initial 
HDL-C level was associated with a significantly 
higher risk of cardiovascular events in STEMI 
patients [15]. However, the design of the above 
studies included the use of a constant value of 
HDL-C, and baseline and angiographic charac-
teristics that might affect clinical outcomes were 
not properly compensated for. In order to rule 
out confounding effects of covariates, a propen-
sity score model was built and two 1:1 cohorts of 
Table 2. The risk of negative clinical outcomes for patients with low and high high-density lipoprotein 
cholesterol (HDL-C) level in the propensity-adjusted cohort.
Low HDL-C High HDL-C
HR (95% CI) P HR (95% CI) P
Cardiovascular death and MI 1.755 (1.274-2.417) 0.001 0.562 (0.275-1.146) 0.113
Cardiovascular death 2.233 (1.465-3.404) < 0.001 0.775 (0.359-1.675) 0.517
Recurrent MI 1.203 (0.725-1.996) 0.474 0.192 (0.027-1.389) 0.102
All-cause death 1.486 (1.084-2.036) 0.014 0.964 (0.556-1.673) 0.897
MACE 1.022 (0.877-1.190) 0.65 0.915 (0.697-1.202) 0.524
CI — confidence interval; HR — hazard ratio; MI — myocardial infarction; MACE — major adverse cardiac event
Figure 2. Survival curves free from cardiovascular (CV) death and myocardial infarction (MI) during follow-up in the 
propensity score-adjusted cohort; HDL-C — high-density lipoprotein cholesterol.
90
92
94
96
98
100
0 200 400 600
Follow-up [days]
No. at risk
Group A
Group B
Group C
4098
3910
661
2691
2637
459
1212
1188
207
551
523
91
Group A (low HDL-C)
Group B (normal HDL-C)
Group C (high HDL-C)
p < 0.001
S
u
rv
iv
a
l 
fr
e
e
 f
ro
m
 C
V
 d
e
a
th
 a
n
d
 M
I 
[%
]
182 www.cardiologyjournal.org
Cardiology Journal 2019, Vol. 26, No. 2
Figure 3. Survival curves free from cardiovascular death and myocardial infarction during follow-up in Group A vs. 
Group B+C (A) and Group A+B vs. Group C (B) in the propensity score-matched cohort; CV — cardiovascular; HDL-C 
— high-density lipoprotein cholesterol; MI — myocardial infarction.
optimally matched patients were obtained in the 
present study. Low initial HDL-C level was found 
to directly correlate with cardiovascular events 
(HR 1.716). Moreover, a consistent result (HR 
1.758) was obtained using IPTW methods. The 
present analysis strengthens the notion that low 
HDL-C levels may be a predictor of cardiovascular 
outcomes in AMI patients.
The vasoprotective effect of HDL-C is thought 
to be related to reverse macrophage cholesterol 
transport [16]. Furthermore, it has been recently 
found that HDL-C facilitates endothelial homeo-
stasis via the increase in nitric oxide production as 
well as the inhibition of critical pathways involved 
in vascular inflammation and endothelial apoptosis. 
It has also been reported that the ability of HDL-C 
to stimulate nitrate oxide production and promote 
endothelial repair is impaired in patients with CAD 
[17]. Based on these observations, the term “dys-
functional HDL-C” was introduced, which indicates 
the loss of anti-inflammatory and vasoprotective ef-
fects [8]. The results of a recent study that used the 
values of > 50 mg/dL for women and > 40 mg/dL 
for men, as a definition of high HDL-C level 
have suggested that higher HDL-C levels are not 
associated with reduced risk of vascular events 
in CAD patients [18]. In the present study, high 
HDL-C level as > 60 mg/dL were defined accord-
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Table 4. Independent predictors of cardiovascular death and myocardial infarction.
Variable Simple Cox regression Multiple Cox regression
HR (95% CI) P HR (95% CI) P
Age (1-year increase) 1.042 (1.029–1.056) < 0.001 1.035 (1.020–1.051) < 0.001
Female sex 1.716 (1.265–2.327) < 0.001
Killip class 3/4 3.281 (2.329–4.621) < 0.001 1.616 (1.106–2.359) 0.001
Ischemic heart disease 1.588( 1.088–2.318) 0.016
Hypertension 1.411 (1.046–1.903) 0.024
Diabetes mellitus 1.570 (1.150–2.143) 0.004
Dyslipidemia 1.058 (0.692–1.618) 0.793
Current smoking 0.768 (0.566–1.042) 0.089
Post-procedural TIMI flow grade 2–3 0.766 (0.284–2.066) 0.598
Three-vessel disease 1.980 (1.458–2.688) < 0.001
Low LVEF 0.947 (0.936–0.959) < 0.001 0.962 (0.948–0.975) < 0.001
Serum glucose level 1.002 (1.001–1.004)) 0.002
Serum creatinine level 1.130 (1.048–1.219) 0.001
Serum peak troponin level 1.001 (1.000–1.001) 0.043
CI — confidence interval; HR — hazard ratio; LVEF — left ventricular ejection fraction; TIMI — thrombolysis in myocardial infarction
ing to ATP III guidelines. According to results of 
the propensity-based analysis, high HDL-C level 
was associated with  reduced risk of cardiovascular 
events (HR 0.449) in AMI patients. This finding 
was confirmed by the use of IPTW methods (HR 
0.632). Therefore, this analysis suggests that high 
initial HDL-C level might protect against cardio-
vascular events in AMI patients. 
Several clinical trials and meta-analyses in-
dicated that raising HDL-C might reduce future 
cardiovascular events and also the atherosclerotic 
burden itself. Several studies which were conduct-
ed based on the modulation of HDL-C by agonizing 
nuclear transcription factors and the enzyme re-
sponsible for HDL metabolism in serum have failed 
to demonstrate the protection against future cardiac 
Table 3. The incidence and risk of negative clinical outcomes in patients with low and high high-density 
lipoprotein cholesterol (LDL-C and HDL-C) level in the propensity-matched cohort.
Low HDL-C Group A  
(n = 3,396)
Group B + C  
(n = 3,396)
HR (95% CI) P
Cardiovascular death and MI 85 (2.5%) 50 (1.5%) 1.716 (1.210–2.434) 0.002
Cardiovascular death 57 (1.7%) 29 (0.9%) 1.981 (1.267–3.099) 0.003
Recurrent MI 28 (0.8%) 21 (0.6%) 1.348 (0.765–2.377) 0.301
All-cause death 78 (2.3%) 58 (1.7%) 1.365 (0.972–1.918) 0.073
MACE 287 (8.5%) 284 (8.4%) 1.007 (0.855–1.187) 0.931
High HDL-C Group A + B  
(n = 1,957)
Group C  
(n = 651)
HR (95% CI) P
Cardiovascular death and MI 52 (2.7%) 8 (1.2%) 0.449 (0.214–0.946) 0.035
Cardiovascular death 34 (1.7%) 7 (1.1%) 0.604 (0.268–1.363) 0.225
Recurrent MI 18 (0.9%) 1 (0.2%) 0.161 (0.021–1.203) 0.075
All-cause death 50 (2.6%) 14 (2.1%) 0.824 (0.456–1.491) 0.523
MACE 162 (8.3%) 57 (8.6%) 1.028 (0.760–1.391) 0.856
CI — confidence interval; HR — hazard ratio; MI — myocardial infarction; MACE — major adverse cardiac event
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events [19]. HDL metabolism and modulation were 
far more complex than was thought, and changes 
in specific circumstances such as disease entity 
and disease progression [20]. Focus now moved 
to modulating various sub-fraction of HDL-C, 
which might lead to reduced residual risk after 
statin therapy [21].
Limitations of the study
The main limitation of the present study is its 
retrospective nature. Despite the use of propensity 
score analysis and sensitivity analysis that em-
ployed the IPTW approach to control for selection 
bias, unidentified confounders may have influenced 
the results. Furthermore, several studies have 
suggested that serum lipid levels after AMI may 
not represent true baseline levels [22], which may 
potentially have affected results. However, other 
reports indicate that HDL-C levels obtained within 
the first 24 to 48 hours subsequent tohospital 
admission are a reliable measure of true baseline 
status [23, 24], which justifiesthis approach to the 
HDL-C level measurements. Finally, lipid profile 
was not monitored during the follow-up period.
Conclusions
Initial HDL-C levels may predict cardiovascu-
lar events in AMI patients undergoing intensive 
statin treatment. In particular, low HDL-C levels 
were associated with increased incidence of car-
diovascular death and recurrent MI. Furthermore, 
high HDL-C levels were possibly associated with 
reduced risk of cardiovascular events, especially 
in STEMI patients, indicating a potential protec-
tive effect.
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